Several studies using a variety of approaches have investigated the impact of the Fc glycan structure on IgG clearance rates. Most, but not all, of these studies have concluded that glycan structural differences do not affect clearance. Here we investigated the impact of glycan on the clearance of a human antibody in humans. To monitor glycandependent changes, a human IgG2 was affinity purified in a single step from serum samples from a human pharmacokinetic study. The glycan profile from the purified antibody samples was determined by RP-HPLC/MS analysis of the 2-aminobenzamide-labeled glycans. Relative levels of high-mannose species (M6-M9) decreased over circulation time. Differences in the individual high-mannose structural isoform clearance rates were measured from extracted ion current profiles. Similar changes to the glycan profile could be achieved through incubation of the antibody in serum in vitro, suggesting that the changes observed in vivo were the result of glycan cleavage, not differential antibody clearance. These results confirm that antibody clearance is not significantly affected by the Fc glycan structure and provide evidence for the presence of circulating mannosidase activity in humans.
Introduction
Circulating glycoproteins can be cleared from the blood by receptors that recognize specific glycan forms. Because of this, much effort has been placed in the biotechnology industry on altering and controlling glycosylation patterns to increase the serum half-life of recombinant protein drugs. Recombinant antibodies expressed in mammalian tissue culture cells are, like endogenous human antibodies, glycoproteins. All endogenous IgG antibodies contain an N-linked glycan in the Fc region and about 20% contain glycans elsewhere on the molecule (Abel et al. 1968; Youings et al. 1996; Jefferis 2005) . Most recombinant antibody drugs have been engineered or selected to contain only the single Fc glycosylation site. While the effect of glycan forms elsewhere on antibodies and on the surfaces of other glycoproteins has been well established (Gross et al. 1987; Macdougall 2002; Huang et al. 2006; Jones et al. 2007; Keck et al. 2008) , the effect of Fc glycan form changes on clearance is less clear. Fc glycans are partially buried within the antibody structure, and this protection is thought to limit their impact on the antibody clearance mechanism.
Several studies have been published in an attempt to determine the impact of Fc glycan changes on serum clearance. Two general approaches have been used in these studies. In one approach, antibodies have been prepared that are enriched in specific glycan forms, either through genetic mutation (Wright and Morrison 1994) , addition of metabolic inhibitors (Zhou et al. 2008 ), a combination of both (Kanda et al. 2007 ), affinity purification (Millward et al. 2008) or enzymatic treatment (Newkirk et al. 1996 ). These antibody samples are then injected into animals to determine the impact on the overall clearance rate. In the other approach, the glycan forms are analyzed after the drug has been administered (Huang et al. 2006; Jones et al. 2007; Keck et al. 2008 ). Changes to the glycan pattern with circulation time are interpreted as differences in clearance rates.
Both approaches have advantages and disadvantages. The enrichment approach has the advantage of directly measuring the drug clearance, not inferring clearance based on glycan changes. However, an assumption is made that the glycan change is the sole difference between the samples. Most studies do not thoroughly demonstrate that the different samples are chemically and structurally identical except for the glycan changes. Glycan heterogeneity in the samples can also lead to some ambiguity in the results. Finally, these studies are limited to animals, typically rats, although the antibodies studied are often human or humanized. The postadministration collection approach can follow many more glycan forms simultaneously than the enrichment approach. Since changes to a single administered sample are followed, the impact of specific microheterogeneity can be monitored without the multiple sample heterogeneity issue linked to the enrichment approach, as mentioned above. Another major advantage is that collected samples can be obtained from human pharmacokinetic (PK) studies, allowing analysis of human antibodies in human subjects. But this approach is indirect, as mentioned above. If another mechanism besides clearance is responsible for the changes in the glycan pattern, the study might falsely interpret this change as differential clearance.
Although several studies on the effect of Fc glycans on antibody clearance using these two approaches have been published, surprisingly, none have followed human antibodies in humans. Here we study the changes to the glycosylation pattern of a recombinant human antibody injected into human subjects. Further experiments addressed whether changes to the glycosylation pattern are from differential clearance or glycan trimming in vivo.
Fc glycan clearance

Material and methods
Materials
The recombinant human IgG2 monoclonal antibody (Mab) used in this study was produced at Amgen (Thousand Oaks, CA) and consists of two gamma2 heavy chains and two kappa light chains. Mab, which binds to human IL-1 receptors, was expressed in CHO cells and highly purified using protein A affinity and ion-exchange chromatography, using well-established protocols (Shukla et al. 2007 ). Peptide-N-glycosidase F (PNGase F) and other glycan assay-related materials were purchased from QA-Bio (Palm Desert, CA). 2-Aminobenzamide (2AB), sodium cyanoborohydride (NaCNBH 3 ), and iodoacetamide (IAM) were from Sigma-Aldrich (St. Louis, MO). Acetonitrile, DMSO, and acetic acid were HPLC-reagent grade. An HT protein express kit, including chips and reagents, was purchased from Caliper Life Sciences (Mountain View, CA). A Hitrap A column was purchased from GE Healthcare (Piscataway, NJ). Actigel ALD Superflow was from Sterogene Bioseparations (Carlsbad, CA).
Preparation of 2AB-derivatized glycans
2AB-labeled glycans were prepared as described previously (Chen and Flynn 2007) with some modifications to optimize for uniform recovery of both sialylated and neutral glycans. Briefly, N-linked glycans were released enzymatically from 20 µg antibody using PNGase F. Protein was then removed from the glycan by a PGC column. TFA (0.1%) was added to the 80% acetonitrile prewash step and 0.05% TFA was added to the 25% acetonitrile in the elution step. A labeling reagent (10 µL of 0.35 M 2AB, 1 M NaCNBH 3 in 70:30 (v:v) DMSO:acetic acid) was added to the dried glycan pool. Excess labeling reagent was removed by S-cartridge after the labeling reaction. A slightly higher concentration of acetonitrile (85% instead of 80%) was used in the wash step, and 2AB-labeled glycans were eluted with 3 × 0.5 mL water. Eluted fractions were combined and brought to complete dryness using a speedvac. The final material was reconstituted in 110 µL water, 100 µL of which was injected for LC/MS analysis.
RP-HPLC/MS analysis
RP-HPLC 2AB-glycan separation was performed as described previously (Chen and Flynn 2007) . Mass spectrometry experiments were conducted using a time-of-flight instrument (LCT premier, Waters) for all the mass spectrometry (MS) data presented here. Glycan structure information was derived from the tandem MS experiments conducted using a linear ion trap instrument (LTQ, Thermo Scientific) operated in negative ion mode.
Human PK study of Mab
A 1000 mg Mab dose was administered to adult human subjects in a single intravenous injection. Blood samples were collected over several weeks at the time points indicated. After allowing time to clot, the clot was separated from serum by centrifugation (2000 × g for 15 min). Serum was stored in cryotubes at −20
• C or colder until use. Mab concentrations in serum were determined with a sandwich ELISA using two anti-idiotypic antibodies against Mab.
Samples collected from two subjects were used in this study. For one of the subjects (subject 1, a 26-year old male), the samples collected at 1 h and 1, 2, 4, 10, and 13 days after administration were used. For the other subject (subject 2, a 21-year old male), the samples used were collected at 1, 2, 4, 12 h and 1, 2, 4, 10 days after administration. A sample was also collected from the second subject 20 min prior to administration as a serum blank.
Mab ligand affinity purification
A small aliquot (0.5 mL) of freshly clarified human serum containing Mab was mixed with 4.5 mL PBS and 0.2 mL of Mab-ligand resin. Mab-ligand resin was prepared according to the manufacturer's procedures. The tube containing the serum:Mab-ligand resin mixture was rocked at room temperature for 4 h. At the end of the incubation, the bound Mab was removed by sedimentation (350 × g for 5 min). The sedimented resin containing the bound Mab was gently resuspended in PBS and transferred to a small plastic column. After washing three times with 5 mL of PBS containing 0.5 M NaCl, the Mab was eluted with 0.5 mL of 10 mM glycine, pH 1.5. The pH of the eluted material was adjusted to approximately 5 with 1 M Tris, pH 8.
Microchip CE-SDS
Microchip CE-SDS analysis was performed under nonreducing conditions on a LabChip 90 instrument (Caliper Life Sciences) (Chow 2006) . Some modifications were made from the manufacturer's suggested protocol. Briefly, a 5 µL antibody sample was mixed with a 35 µL denaturation solution. The denaturation solution was prepared by mixing 700 µL HT protein express sample buffer with 70 µL 250 mM IAM. The samples were incubated at 70
• C for 15 min, after which 70 µL of water was added to each sample before loading onto the instrument for analysis. The concentration of each sample was calculated by comparing the main peak area with a standard curve established from the Mab standard at a series of concentrations.
Quantification of clearance rates
The Mab concentration determined by ELISA and the percentage distribution of different glycans determined by RP-HPLC/MS of 2AB-labeled glycans were used to calculate the concentrations of antibodies containing different glycans at different time points. For most glycans, the peak area in the fluorescence chromatogram was used to determine their relative levels. With unresolved or partially resolved glycan species (e.g., G1, G2, and all high-mannose forms except for M5), the peak area from their corresponding MS-EIC chromatogram was used. In the latter cases, the peak area in the extracted ion current (EIC) chromatogram was compared to that of M5 and normalized to the concentration of M5 determined from the fluorescence signal. M5 was chosen because it is relatively abundant and well resolved from other species.
The dosages of different glycoforms were calculated by multiplying their percentages at the 1 h postdosing time point and the dosage of the total Mab (1000 mg). The apparent clearance rate was obtained by dividing the dosage by the area under the curve (AUC) in the concentration versus time plot. The relative clearance rate was calculated by dividing the clearance rate of different glycoforms to that of the total Mab. 
Incubation of Mab in serum in vitro
Blood serum collected from multiple adults was combined and centrifuged in 1 mL aliquots at 20,000 × g (k-factor of ∼500) at 4
• C for 30 min. The top 0.5 mL supernatant fraction from each tube was collected and combined. Sodium azide and CaCl 2 were added to achieve final concentrations of 1 mM and 30 mM, respectively. Mab (60 µg) was spiked into 0.5 mL of centrifuged blood serum and incubated at 37
• C for 0, 15, and 24 h, followed by affinity purification and 2AB glycan analysis, as described above.
Results and discussion
Glycan map method A reversed-phase HPLC glycan map method, previously developed, was used to characterize antibody Fc glycans (Chen and Flynn 2007) . This method is highly resolving (Figure 1 ), generating 29 fluorescent 2AB-labeled glycan peaks for the Mab used in this study. The glycan structures identified from the numbered peaks shown in Figure 1 are illustrated in Figure 2 . Another major advantage is the method's MS compatibility. MS can not only be used online for structural determination, but also be used as an alternative detector to quantify unresolved fluorescent peaks. When used for glycan characterization, the method can quantify glycans to 160 fmol using the fluorescence signal and to 320 fmol using the MS signal on a Waters LCT electrospray time-of-flight instrument (based on a signal to noise ratio = 10 for the fluorescence and EIC chromatograms). Protein is not limiting for this purpose, so 100 µg or more of an antibody is typically used. To be useful in an antibody clearance study, however, the method must be able to quantify glycans from samples containing low antibody concentrations. Therefore, sensitivity of the method was addressed. Results indicated that the glycan preparation steps yielded similar recovery and glycan profiles when starting with amounts ranging from 1 mg to 10 µg antibodies (data not shown). Some minor changes were made to the 2AB glycan preparation steps from that described previously (Chen and Flynn 2007) to ensure that all glycan types were recovered uniformly (Material and methods). The same 29 fluorecent peaks detected when starting with 1 mg antibody were also detected when starting with 10 µg antibody. To ensure accurate measurements in the clearance study, protein loads for the glycan preparations were adjusted to similar levels (20 µg), and the method was capable of measuring minor glycans comprising 0.06% of the total using the fluorescence signal and 0.12% using the MS signal. This sensitivity and resolution allows the monitoring of a large number of relatively low abundance glycans in this study.
Clearance study and Mab isolation from serum
Mab, a fully human IgG2, was injected into healthy adult subjects as part of a phase 1 clinical trial. Dosages of up to 1000 mg per subject were administered intravenously. Mab was isolated from the withdrawn serum by affinity purification using the antibody's ligand. This isolation procedure was capable of obtaining 70% of the Mab from the serum at over 95% purity, as judged by microchip CE-SDS (Figure 3 ). To determine whether this level of purity was sufficient for monitoring changes to the glycan profile in this study, the glycan map from Mab was compared before and after isolation from a subject's serum sample. In general, the relative levels of the glycans are preserved following the isolation procedure, except for some sialylated biantennary glycans, as indicated in Figure 4B , which were also found in ligand affinity preparations from the serum of subjects that have not been treated with Mab ( Figure 4C ). Since the majority of these sialylated glycans are impurities in the Mab glycan map, they could not be monitored in this study. Glycan maps from one subject's PK samples of up to 13 days, normalized against the major glycan species (G0F), are shown in Figure 5A . All major glycan peaks overlapped, indicating that no changes to the relative levels of these glycans over time in vivo were observed. However, some differences were seen in the minor glycan species. Peaks representing certain high-mannose species (M6-M9) appeared to diminish in relative intensities over time in the body. Most of the changes to these minor peaks were observed in the first two days. This can be seen more easily in the Figure 5B , a chromatogram expanded in the region containing several high-mannose species. Only early time points are shown for clarity.
Apparent clearance rates
Mab PK profiles indicate multiple clearance phases, a more rapid initial phase followed by additional slower phases Figure 1 . Glycan structures were determined by MS n analysis. Abbreviations and the peak numbers are listed under each structure. Peak numbers with a lowercase letter indicate that more than one structure was found within that fluorescent peak. Black squares represent GlcNAc, white circles represent Man, white triangles represent Fuc, white diamonds represent Gal, and black stars represent sialic acid. Connecting lines do not indicate linkages.
( Figure 6 ). The entire fast initial phase and a portion of the slower second phase were monitored in this study. Approximately half the initially measured serum concentrations remained in these two patients after 4-5 days, which indicates somewhat faster clearance than reported for IgG2 in myeloma patients (Morell et al. 1970) . The influence of the Mab target on overall clearance was not addressed. If we assume that the changes in the glycan profile over time result from the differential clearance of the attached antibody, the antibody clearance rates could be calculated for each glycoform. Table I lists the average apparent clearance rates associated with each glycan relative to that of the Mab and the range of values obtained using the fluorescence signal. Similar relative clearance rates were calculated for all the major glycans. Many minor glycans, such as monosialylated, hybrid, and triantennary glycans, generated similar values. In contrast, the partially resolved high-mannose M6 through M9 peaks appeared to clear faster, about 40% faster than the general Mab clearance rates, though the more abundant high-mannose form M5 did not.
Some fluorescent peaks, including several of the minor glycan forms contained multiple glycan species. Therefore, the fluorescence signal could not reliably quantify certain individual glycans. But since the unresolved glycan species differ in mass, MS detection with EIC was able to specifically quantify these species. In Figure 7 , the MS total ion current (TIC) chromatogram is compared to the fluorescence signal chromatogram for the high-mannose species. Similar relative intensities of the two profiles indicate that the MS ionization efficiencies are similar among the glycans shown.
EIC chromatograms were generated for all high-mannose species (Figure 8 ). Dashed lines and number labels represent the TIC chromatographic peaks. As shown on the individual HM-EIC chromatograms, several of the HM glycans resolve into multiple peaks (e.g., M7 has three significant peaks). Each peak was identified through MS n fragmentation studies (data not shown). Results from these fragmentation studies, summarized in Figure 9 , reveal that the structural isomers of all the high-mannose species can be resolved and quantified by RP-HPLC/MS.
Using EIC, changes in relative levels for each high-mannose glycan and for each structural isoform within each glycan were determined (Table II) . The concentration of M5 determined from the fluorescence signal was used to calculate the concentrations of the species listed in Table II by comparing the peak areas from the EIC chromatograms. MS results mirror those obtained through fluorescence detection, showing several high-mannose species changes in relative intensity over time in subjects. Interestingly, structural isoforms change at different rates. For example, the M8 isoform 1 diminishes about 2.3-fold faster than isoform 3. Likewise, differences are seen in the structural isoforms of M7. A comparison of the changes to the M6-M8 structural isoforms reveals common features of the faster clearing glycans. For example, the relative levels of isoforms of M6, M7, and M8 species lacking the middle arm α-1,2-mannose decrease more quickly than some of the other isoforms (Table II and Figure 9 ). As described earlier, the antibody collection approach, such as was used in this study, infers differences in antibody clearance from the changes in relative levels of the glycans over time in vivo. Yet another mechanism could account for the high-mannose changes observed. Two clues suggest that glycan conversion, not clearance, is responsible for the faster loss of the M6-M9 high-mannose forms. First, the relative levels of M5 increased slightly over the first day after Mab injection. Though small, this increase appears to coincide in time and magnitude with the decrease in the M6-M9 levels ( Figure 10 ). The removal of the α-1,2-linked mannose residues on the larger HM species through enzymatic hydrolysis could generate M5. The differential clearance of M6-M9, on the other hand, would cause minor increases in the relative levels of all glycans, not just M5. However, there are no noticeable increases in other glycans ( Figure 10 ). Second, a bias between structural isoforms is reminiscent of enzymatic specificity found among the mannosidase l enzymes (Tremblay and Herscovics 2000) . For example, the Golgi mannosidase l enzymes preferentially cleave mannose from specific arms on different high-mannose species. Similar specificity has not yet been described for high-mannose receptors.
Human serum was tested for mannosidase activity using Mab glycan substrates. Blood was collected from healthy subjects. After allowing time for clotting, the fresh serum was prepared by sedimentation at 3000 × g. The supernatant was aliquoted and stored frozen. Before use, the thawed serum was centrifuged for 20,000 × g for 30 min at 4
• C to remove microsomes and other cell debris. Many intracellular mannosidases are integral membrane proteins residing in the ER, Golgi, and lysosomes. Cell breakage during serum preparation could generate small membrane-bound particles that would not be expected to sediment under the mild serum preparation conditions used in the previous serum mannosidase Rates, which are the average from two subjects, were normalized to the overall antibody clearance rate, so are unitless. Error values represent the range from these two subjects. study (Porwoll et al. 1999) . The more stringent centrifugation step was added in this study to remove potential microsomal contamination.
Mab was spiked into clarified human serum and incubated at 37
• C. At indicated times, Mab was affinity purified from the serum and the glycan from Mab was analyzed. Relative levels of the larger HM species decreased with the corresponding increase to M5, indicating the presence of α-1,2-mannosidase activity. An overlay of the changes to the overall M6-M9 and M5 changes in vivo and in vitro is shown in Figure 11 . The striking similarity between the conversion observed in vitro and the changes observed in vivo suggests that trimming of the terminal mannose residues is responsible for the changes to the relative amounts of certain HM species in vivo. Moreover, the loss of HM structural isomers in vivo also matches the loss in vitro (see Figure 12 for M7 isoforms as examples). Taken together, these results provide compelling evidence that mannosidase activity circulates in serum and trims HM structures in vivo.
Conclusions
Concern over the potential effects of the glycan structures on antibody clearance arose because certain receptors, such as the asialoglycoprotein and mannose receptors, are known to bind and clear specific glycan types. The asialoglycoprotein receptors bind terminal Gal residues (Stockert 1995) , and the Man receptors clear glycoproteins with terminal Man or GlcNac sugars (Stahl 1992) . Recombinant antibodies expressed in tissue culture cells contain predominantly neutral glycans with varying levels of terminal Gal and some high-mannose structures at the Fc site (Bailey et al. 2005; Kamoda et al. 2006; Chen and Flynn 2007) . If Fc glycan structures govern antibody clearance rates, changes to the relative levels of certain glycans could impact antibody drug efficacy. In most studies published to date, the Fc glycan was determined to not impact antibody clearance in mammals. One study (Newkirk et al. 1996) found a correlation between the terminal sugar on the complex glycan and clearance rates using mouse antibodies in mice. The removal of Gal (G0F) resulted in increased circulation times (+33%). However, the glycans were analyzed with lectin dot blots, providing only semiquantitative estimates of the glycan profiles. Terminal galactose had a seemingly opposite effect on the clearance of a humanized antibody in mice (Huang et al. 2006 ) and an Fc fusion protein (Jones et al. 2007; Keck et al. 2008) in humans, but only for the nonFc glycans. Two studies in mice have determined that an IgG1 with M5 glycan cleared faster than one with complex glycans (Wright and Morrison 1994; Kanda et al. 2007 ), while another study using larger high-mannose glycans found no effect. Other studies monitoring the effect of Fc high-mannose found no impact (Huang et al. 2006; Jones et al. 2007 ).
Our results have extended Fc glycan clearance studies to human antibodies in human circulation. Fc glycan had no significant effect on the clearance of an IgG2 antibody. These results support previous findings and show that rodents were effective surrogates for human antibody clearance studies (Millward et al. 2008; Zhou et al. 2008 ). Although our study was performed on an IgG2 antibody, it might be expected that the Fc glycan would likewise not impact the clearance of other IgG classes, though this remains to be determined. The Fc glycan profile and protein sequence are fairly similar between subclasses, which could result in a similar degree of glycan exposure.
In previous studies, specific high-mannose species had not been individually monitored, either because the antibodies studied using the enrichment approach contained a mixture of HM forms (Millward et al. 2008; Zhou et al. 2008) or because the levels were too low to monitor using the glycan analysis approach used in the studies. One study did monitor the effect of high mannose containing mainly a mixture of M8 and M9 on a human antibody clearance in rats (Zhou et al. 2008) . In our human clearance study, the fairly high subject dosing (1000 mg) coupled with the sensitive highly resolving RP-HPLC/MS glycan assay enabled us to monitor all high-mannose species, down to low relative glycan levels.
This study also illustrates the pitfalls of using changes to the glycan structure as an indicator of differential clearance. The apparent faster loss of specific high-mannose species was the result of glycan trimming in vivo, not differential clearance. In future studies, alternate mechanisms, such as conversion, should be evaluated as explanations for the changes observed. The collection approach does allow for the study of multiple chemically distinct variants simultaneously from a single PK study. For this Mab study, other microheterogeneity, such as recently discovered IgG2 disulfide variants Wypych et al. 2008) , was also monitored. Disulfide variant levels change after injection, but due to disulfide conversion, not differential clearance .
The loss of high-mannose species in vivo could be replicated quite closely in vitro by incubating the Mab in human serum, not only in the rates for individual HM species but also for the structural isoforms within those species. These results strongly argue for the presence of a circulating mannosidase activity in vivo. One preliminary report described the detection of α-1,2-mannosidase activity in serum through in vitro incubation, though no subsequent characterization studies have followed up on this observation (Porwoll et al. 1999) .
The α-1,2-mannosidase I enzymes in the ER and Golgi display different preferences between the high-mannose isomers (Tremblay and Herscovics 2000) . The mannosidase activity described here, which could be one or a mixture of enzymes, also displays high-mannose isomer preferences. Mannose on the middle arm is cleaved more slowly on M6, M7, and M8. This preference seems more aligned with the Golgi mannosidase I activity than the ER activity. The explanation for changes Averages and errors were determined as stated in Table I . a The concentrations of the glycan species used to determine the clearance rates were calculated by comparing the peak areas in the EIC chromatogram to that of M5. The concentration of M5 was determined from the fluorescence signal. 
Percent G1F and G2F
M6-M9 M5 G1F G2F Fig. 10 . Changes to high-mannose species over time in humans. Values represent the relative levels based on the fluorescence (G1F, G2F, and M5) and EIC (M6-M9) area of the 2AB-labeled glycans. Data points at 1 h and 1, 2, 4, 10 days are average values of two subjects, with the error bars representing the range. The error bars for G2F and some G1F data points are smaller than the data symbol and thus cannot be seen. Time is days in circulation. Two glycans, G1F and G2F, are provided to show a major and minor glycan form that change little as a fraction of the total glycan. observed in the minor M4 glycan form in vivo (Table II) are not yet clear. Since the linkage of the terminal mannose sugar has not been determined, it is not known whether a 1,2 linkage or other linkage is cleaved. It is possible that mannosidases with different substrate specificities circulate as well.
What is the source of the circulating mannosidase? Mannosidases within the secretory pathway are type II integral membrane proteins and reside in the ER and Golgi, responsible for the trimming of the maturing N-linked glycans (Vallee et al. 2000) . Proteolytic cleavage of the catalytic domain could Comparison of M7 structural isoforms changes in vivo with changes in vitro. The in vivo and in vitro comparison of changes to M7 glycan forms is as described in Figure 11 , and the EIC areas were used. Individual structural isoforms of M7 are shown. See Figure 9 for structural representations of the individual isoforms.
result in the export of active mannosidase to the serum (Porwoll et al. 1999) . Mislocalization of lysosomal mannosidase might also result in a portion exiting cells. Alternatively, mannosidase may be synthesized as a soluble secreted form. A survey of the human genome reveals multiple predicted mannosidases with cleavable signal sequences. Whether the circulating mannosidase is the result of cleavage, mislocalization, or a specific circulating form, is the subject of future study.
